Outlook Therapeutics (OTLK) EBIAT (2016 - 2025)
Outlook Therapeutics (OTLK) has disclosed EBIAT for 8 consecutive years, with -$13.5 million as the latest value for Q4 2025.
- On a quarterly basis, EBIAT rose 37.59% to -$13.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$70.1 million, a 49.37% decrease, with the full-year FY2025 number at -$64.0 million, up 15.11% from a year prior.
- EBIAT was -$13.5 million for Q4 2025 at Outlook Therapeutics, up from -$14.8 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of -$13.5 million in Q4 2025 to a low of -$21.6 million in Q4 2024.